Every material Form 8-K Chemed filed with the SEC in 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Chemed's board appointed Michael D. Witzeman, the company's Vice President and Controller, as Chief Financial Officer effective January 1, 2024. The change follows the retirement of David P. Williams from the CFO role, and Witzeman will also continue as Controller and Vice President.
Michael D. Witzeman appointed CFO by the board on December 18, 2023, effective January 1, 2024
Replaces David P. Williams, who is retiring from the CFO role
Witzeman joined Chemed in 2005 after Deloitte & Touche LLP and is a licensed CPA
Witzeman will keep his Controller and Vice President roles
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Chemed filing is on SEC EDGAR ↗. 8-K briefs of other companies →